Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Stock code：600380 Stock abbreviation：健康元
Joincare Pharmaceutical Group Industry Co., Ltd
2022 First Quarterly Report
Board of Directors (the “Board”) and all Directors of the Company hereby warrant that there are no
false representations, misleading statements or material omissions contained in this report, and
severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the
contents of the Report.
IMPORTANT NOTICE
(I) The Board, the Supervisory Committee and the Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of
quarterly reports, and that there are no false representations, misleading statements or material
omissions contained in the Report, and severally and jointly accept responsibility.
(II) The person-in-charge of the Company, the person-in-charge of the Company's accounting work
and the person-in-charge of the accounting department (the head of the accounting department)
hereby warrant the truthfulness, accuracy and completeness of the financial statements
contained in quarterly reports.
(III) Whether the first quarterly financial statements are audited
□Applicable √N/A
(IV) The Report is prepared in both Chinese and English. In case of any ambiguity in the
understanding of the Chinese and English texts, the Chinese version shall prevail.
I Principal Financial Data
(I) Principal accounting data and financial indicators
Unit: Yuan Currency: RMB
The Reporting Period:
Item Year-on-Year Change (%)
(January-March 2022)
Revenues 4,657,343,538.89 12.36
Net profit attributable to Shareholders of
460,537,813.53 25.52
the listed company
Net profit attributable to Shareholders of
the listed company after deducting the 457,193,702.95 36.47
extraordinary gain or loss
Net cash flow from operating activities 871,904,476.98 76.27
Basic earnings per share (RMB/share) 0.2411 28.49
Diluted earnings per share (RMB/share) 0.2410 28.72
Weighted average return on net assets (%) 3.84 Increased by 0.58 percentage points
1 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Change from the end
End of the of the previous year to
End of the Previous Year
Reporting Period the end of the
Reporting Period (%)
Total assets 32,275,092,753.15 31,103,900,389.29 3.77
Owners’ equity attributable
to Shareholders of the listed 12,073,975,596.59 11,820,293,656.69 2.15
company
Note: During the Reporting Period, the Company recorded revenues of RMB 4,657 million,
representing an increase of 12.36% year-on-year; the main driver of the growth is steady increasing
sales volume of main product categories in key specialist arenas. During the first quarter of 2022,
Revenues from chemical drug preparation products amounted to RMB 2,737 million, representing
an increase of 24.54% year-on-year, of which, Revenues from Inhalation products amounted to 363
million, representing an increase of 324.90% year-on-year; Revenues from anti-infective drugs
amounted to RMB 350 million, representing an increase of 26.91% year-on-year; Revenues from
gastroenterology products amounted to RMB 1,070 million, representing an increase of 5.90% year-
on-year; Revenues from gonadotropic hormones products amounted to RMB 737 million,
representing an increase of 22.84% year-on-year; Revenues from APIs and intermediates amounted
to RMB 1,406 million, representing an increase of 14.90% year-on-year. The Revenues from
traditional Chinese medicine preparations amounted to RMB 283 million, representing a decrease
of 33.53% year-on-year. The Revenues from diagnostic reagents and equipment products amounted
to RMB162 million, representing a decrease of 30.77% year-on-year.
(II) Items and amounts of extraordinary gains and losses
Unit: Yuan Currency: RMB
Amounts for the
Item Explanation
Reporting Period
Gains and losses on disposal of non-current Proceeds from disposal of fixed
-374,417.51
assets assets
Government grants included in profit and
loss for the Period (except for government
grants closely associated with normal Government grants through the
56,644,887.24
corporate businesses, entitled at fixed profits and losses for the Period
amount or fixed level according to national
policies and national unified standards)
Gains and losses on fair value changes
derived from holding of financial assets held
for trading, derivative financial assets,
financial liabilities held for trading, Gains or losses arising from
derivative financial liabilities, and changes in fair value of financial
investment income generated on disposal of assets/liabilities held for trading,
-45,275,532.62
financial assets held for trading, derivative and investment gains from holding
financial assets, financial liabilities held for and disposal of financial
trading, derivative financial liabilities and assets/liabilities held for trading
other debt investments, except for effective
hedging activities related to the ordinary
operating business of the Company
Other non-operating Revenues and non- Other non-operating Revenues and
operating expenditures apart from the above 241,415.42 non-operating expenditures apart
items from the above items
Effect of the above items on
Less: Income tax effect 9,124,665.76
income tax
The portion of the above items to
Effect of minority interests after tax -1,232,423.81 which minority shareholders are
entitled
Total 3,344,110.58
2 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
The explanation on the recognitions of the items of extraordinary gains and losses as set out in the
“Interpretative Announcement for Information Disclosure of Companies that Issue Securities to the
Public No. 1 – Extraordinary Gains or Losses” as items of recurring gains and losses
□Applicable √N/A
(III) Changes and the reasons for changes in principal accounting data and financial indicators
√Applicable □N/A
Name of item Change in proportion（%） Explanation
Net profit attributable to Mainly due to the growth of the sales
Shareholders of the listed revenues from the chemical drugs and
36.47
company after deducting the APIs products, which is the main driver
extraordinary gain or loss of the growth of the net incomes.
Net cash flow from operating Mainly due to an increase of cash
76.27
activities collections of sales revenues.
（IV）Substantial changes of other items in the Financial Statements and financial indicators and
reasons thereof
Unit: Yuan Currency: RMB
Change in
Balance Sheet 2022/03/31 2021/12/31 proportion Main Reason
（%）
Short-term loans 1,655,807,901.10 2,518,484,835.09 -34.25 Mainly due to repayment of loans in the Period.
Mainly due to part of the contract payments received
Contract liabilities 124,089,632.31 234,140,702.29 -47.00 in advance in the Period which met the conditions for
revenue recognition were transferred to revenues.
Mainly due to an increase in enterprise income tax
Taxes payables 382,548,978.08 270,618,183.41 41.36
payables.
Mainly due to an increase of new long-term loans by
Long-term loans 1,816,661,809.48 826,780,252.78 119.73
subsidiaries in the Period.
Mainly due to the share repurchased during the current
Treasury shares 472,590,296.96 222,644,454.50 112.26
period.
Other
Mainly due to the disposal of stocks of China Galaxy
comprehensive -87,498,451.08 5,387,545.97 -1724.09
Securities Co., Ltd. held during the Period.
income
Change in
Income Statement 2022 Jan.-Mar. 2021 Jan.-Mar. proportion Main Reason
（%）
Mainly due to the increase in the investment incomes
Investment incomes 29,176,808.52 21,812,732.70 33.76
from associate investments held in the current period.
Gains from changes Mainly due to fluctuations in the market value of subject
-54,151,999.18 -39,393,074.92 N/A
in fair value securities investment held.
Mainly due to the recovery of the accounts receivables
Credit impairment with relatively long ages in the current period which
217,773.10 -3,611,272.93 N/A
loss offset the expected credit losses accrued in the previous
period.
Mainly due to a decrease in the provision for inventory
Asset impairment
-5,309,013.21 -22,802,167.34 N/A depreciation in the current period as compared with the
loss
previous period.
Gains from disposal Mainly due to losses occurred from disposal of fixed
-370,357.71 21,927.78 -1788.99
of assets assets in the current period.
Non-operating
2,321,933.96 24,072,371.67 -90.35 Mainly due to the land disposal in the previous period.
income
Non-operating Mainly due to larger non-profit donation expenditure in
2,084,578.34 3,257,611.14 -36.01
expenditure the previous period.
Other
comprehensive net Mainly due to changes in the fair value of other equity
-106,847,774.60 -166,618,134.73 N/A
income after instrument investments.
taxation
3 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Change in
Cash Flow proportion
2022 Jan.-Mar. 2021 Jan.-Mar. Main Reason
Statement
（%）
Net cash flow from Mainly due to an increase of cash collections of sales
871,904,476.98 494,649,514.25 76.27
operating activities revenues.
Mainly due to the increase in cash inflow from
Net cash flow from
investing activities caused by the disposal of stocks of
investment -77,907,837.67 -269,420,918.38 N/A
China Galaxy Securities Co., Ltd. held during the
activities
Period.
Net cash flow from Mainly due to an increase of new long-term loans in
62,714,553.34 -542,754,908.85 N/A
financing activities the current period.
Effect of changes in
Mainly due to an increase of exchange losses on
foreign exchange
-12,259,201.98 3,666,733.44 -434.34 foreign currency funds held as a result of the
rates on cash and
fluctuations in exchange rates.
cash equivalents
Net increase in cash Mainly due to an increase of cash from daily operating
and cash 844,451,990.66 -313,859,579.54 N/A activities of the Company and an increase of new long-
equivalents term loans.
II Shareholders' Information
(I) Table of the total number of ordinary shareholders, the number of preferred shareholders with
resumed voting rights and shareholdings of the top 10 shareholders
Unit: Shares
Total number of preferred
Total number of ordinary
shareholders with resumed voting
shareholders at the end of 102,434 0
rights at the end of the Reporting
the Reporting Period
Period (if any)
Shareholdings of the top 10 shareholders
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholders Share
shareholders shares (%) with selling Number
status
restrictions
Shenzhen Baiyeyuan Domestic
non-state-
Investment Co., Ltd. * (深圳 895,653,653 46.85 0 Pledge 95,679,725
owned legal
市百业源投资有限公司)
person
Hong Kong Securities
Unknown 127,833,815 6.69 0 Unknown
Clearing Company Limited
Overseas legal
Might Seasons Limited 57,487,434 3.01 0 Unknown
person
108 portfolio of national
Unknown 11,461,721 0.60 0 Unknown
social security fund
Huaxia Life Insurance Co.,
Unknown 9,275,718 0.49 0 Unknown
Ltd. - proprietary fund
16011 portfolio of basic
Unknown 9,050,234 0.47 0 Unknown
endowment insurance fund
Bosera Funds Management
Co., Ltd. - 419 portfolio of Unknown 8,732,946 0.46 0 Unknown
social security funds
Domestic
He Zhong 7,800,024 0.41 0 Unknown
natural person
Abu Dhabi Investment Overseas legal
5,417,816 0.28 0 Unknown
Authority person
Agricultural Bank of China
Limited - China 500
Exchange Traded Open-End Unknown 4,690,194 0.25 0 Unknown
Index Securities Investment
Fund (ETF)
4 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable Class and number of shares
Name of shareholders shares held without
Class Class
selling restrictions
Shenzhen Baiyeyuan Investment Co., Ltd. * Ordinary shares
895,653,653 895,653,653
(深圳市百业源投资有限公司) denominated in Renminbi
Hong Kong Securities Clearing Company Ordinary shares
127,833,815 127,833,815
Limited denominated in Renminbi
Ordinary shares
Might Seasons Limited 57,487,434 57,487,434
denominated in Renminbi
Ordinary shares
108 portfolio of national social security fund 11,461,721 11,461,721
denominated in Renminbi
Huaxia Life Insurance Co., Ltd. - proprietary Ordinary shares
9,275,718 9,275,718
fund denominated in Renminbi
16011 portfolio of basic endowment insurance Ordinary shares
9,050,234 9,050,234
fund denominated in Renminbi
Bosera Funds Management Co., Ltd. - 419 Ordinary shares
8,732,946 8,732,946
portfolio of social security funds denominated in Renminbi
Ordinary shares
He Zhong 7,800,024 7,800,024
denominated in Renminbi
Ordinary shares
Abu Dhabi Investment Authority 5,417,816 5,417,816
denominated in Renminbi
Agricultural Bank of China Limited - China
Ordinary shares
500 Exchange Traded Open-End Index 4,690,194 4,690,194
denominated in Renminbi
Securities Investment Fund (ETF)
There was no connection or acting-in-concert relationship between
Description of connection or acting-in-concert Shenzhen Baiyeyuan Investment Co., Ltd., the controlling shareholder
relationship of the above shareholders of the Company, and other shareholders; whether there is connection or
acting-in-concert relationship among other shareholders is unknown.
Description of the participation of the top 10
Shareholder He Zhong held 800,000 shares through an ordinary
shareholders and the top 10 shareholders
securities account and 7,000,024 shares through a customer's margin
without selling restriction in securities margin
account, namely 7,800,024 shares in total.
trading and securities financing (if any)
As at the end of the Reporting Period, the special repurchase account of
Notes on the special repurchase account among the Company (special securities repurchase account of Joincare
the top 10 shareholders Pharmaceutical Group Industry Co., Ltd.) owned 38,402,584 shares in
total, accounting for 2.01% of total share capital of the Company.
III Other Information
Other key information on the operations of the Company during the Reporting Period to which
investors should be reminded to pay attention
√Applicable □N/A
1.Use of proceeds
Pursuant to the “Resolution on Change of Certain Projects Invested with Proceeds” considered
and approved at the 8th meeting of the 8th Session of the Board of the Company on 24 January
2022, it was agreed that Zhuhai Health Industry Base Construction Project was changed to the New
Product R&D Project, Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion
Project and the Information Platform Construction Project. The resolution was approved at the 2022
1st extraordinary general meeting of the Company on 11 February 2022.
Before the alteration of the projects invested with the Proceeds is as follows:
5 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Unit: 10,000 Yuan
Total Total amount Use of proceeds Balance of
Project name amount of of proceeds as at 31 proceeds as at 31
investment investment December 2021 December 2021
Zhuhai Health Industry Base Construction
Project（珠海大健康产业基地建设项 98,066.84 76,974.02 3,386.29 73,587.73
目）
Haibin Pharma Pingshan Pharmaceutical
Industrialization Base Project（海滨制药 125,471.35 90,000.00 66,745.58 23,254.42
坪山医药产业化基地目）
Total 223,538.19 166,974.02 70,131.87 96,842.15
Given the facts that the “Zhuhai Health Industry Base Construction Project” has been
postponed for several times for not meeting the conditions for commencement, and the market
environment and the Company's business situation have changed, which resulted in changes in the
project feasibility, that the Company has an urgent need of funds for R&D investment and other
projects, and that other financing channels are time-consuming and costly, the Company changed
the aforementioned project to the New Product R&D Project, Haibin Pharma Pingshan
Pharmaceutical Industrialization Base Expansion Project and the Information Platform Construction
Project. See below for details:
Unit: 10,000 Yuan
Before alteration After alteration
Total
Total Total amount
Total amount amount of
Project name amount of of proceeds Project name
of investment proceeds
investment investment
investment
New Product R&D Project
110,000.00 54,587.73
(新产品研发项目)
Haibin Pharma Pingshan
Zhuhai Health Pharmaceutical
Industry Base Industrialization Base
Expansion Project (海滨制 18,139.39 16,000.00
Construction Project 98,066.84 76,974.02
（珠海大健康产业 药坪山医药产业化基地扩
基地建设项目） 建项目)
The Information Platform
Construction Project (信息 3,000.00 3,000.00
化平台建设项目)
Total 98,066.84 76,974.02 Total 131,139.39 73,587.73
The details of alteration of the projects invested as follows:
(1) The New Product R&D Project
The total investment amount of the project is RMB 1,100,000,000, in which RMB 545,877,300
is raised, mainly for the research and development of inhalation preparations, complex injections,
and new drug delivery devices among others. In particular, the investment is used to acquire R&D
equipment, pre-clinical and clinical R&D inputs. Main products involved in this project are: 1)
Respiratory drugs: the main purpose of the project as a part of the Company's strategic layout in the
respiratory drug market, in a bid to increase sources of profit and enhance the Company's
comprehensive competitiveness in the pharmaceutical market; 2) Complex injections: mainly
6 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
micronano injections. The Company has built a complex injection technology development platform,
specializing in the development of special injection products such as nanocrystals, microcrystals,
liposomes and emulsions. The micronano preparations proposed with this platform will be
developed based on existing drugs with exact clinical value to further expand the clinical use of the
drug; 3) New drug delivery devices: to be developed based on the progress of R&D of drugs for
respiratory diseases, so as to improve the industrial chain of core products, and enhance the added
value and core competitiveness of products to be marketed.
(2) Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project
The total investment amount of this project is RMB 181,393,900, in which RMB 160,000,000
is raised. Expanded from the Haibin Pharma Pingshan Pharmaceutical Industrialization Base
Expansion Project, this project established new production lines of Tobramycin Solution for
Inhalation, Fluticasone Propionate Suspension for Inhalation, among others and expanded existing
production lines of Budesonide Suspension for Inhalation and Levosalbutamol Hydrochloride
Nebuliser Solution. This project is implemented for two key reasons: 1) New products are to be
marketed, which requires related production lines. With inhalation preparations incorporated in its
key layout in recent years, the Company has continuously invested in the R&D of several new
products with high clinical value and broad market space. As new products like Tobramycin
Solution for Inhalation and Fluticasone Propionate Suspension for Inhalation are to be marketed,
related production lines are necessary to make preparation for commercial production. 2) The
capacity is unable to meet demand of some products: Budesonide Suspension for Inhalation was
involved in the fifth batch of national centralized drug procurement in June 2021, and will be
supplied to public hospitals in 7 domestic provinces, meeting 70% of the drug needs according to
policies. Levosalbutamol Hydrochloride Nebuliser Solution is the first approved exclusive generic
drug in China. As at the date the resolution got approved (January 24, 2022), no originator
manufacturers or other generic drug manufacturers have been approved for market in China.
However, the market demand is huge. The original capacity of the above two products is unable to
meet such market demand, making capacity expansion a must.
(3) The Information Platform Construction Project
The total investment amount of this project is RMB 30,000,000, in which RMB 30,000,000 is
raised. The investment is used to purchase information management software and hardware as well
as computer room facilities. The project planned to upgrade and improve: the information
infrastructure of existing information management system, including disaster recovery and
7 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
infrastructure of the server, and security equipment; financial management system, including
financial sharing system and tax administration system; group management and control system,
including HR system and SAP system.
2. Matters about share repurchase
Pursuant to the Resolution on Share Repurchase Scheme by Way of Centralized bidding
transactions and other resolutions considered and approved at the 6th Meeting of the 8th Session of
the Board and the 2021 Fifth Extraordinary General Meeting of the Company on 6 December 2021
and 23 December 2021, it was approved that the Company repurchased company shares by way of
Centralized bidding transactions with its own funds; the total amount of repurchase funds should be
no less than RMB 300 million (inclusive) and no more than RMB 600 million (inclusive); the
repurchase price should be no more than RMB 15/share (inclusive); the repurchase term should be
no more than 12 months from the date when the repurchase scheme was approved by the General
Meeting of the Company. For the details, please see the Announcement of Joincare Pharmaceutical
Group Industry Co., Ltd. on the Share Repurchase Scheme by Way of Centralized bidding
transactions (Lin 2021-145) and the Repurchase Report of Joincare Pharmaceutical Group Industry
Co., Ltd. on Share Repurchase by Way of Centralized bidding transactions (Lin 2022-002). On 20
January 2022, the Company initially repurchased 785,992 shares by way of Centralized bidding
transactions, representing 0.04% of total share capital (1,907,727,908 shares) of the Company. The
aggregate amount of funds used for the repurchase was RMB 9.981 million (including the
transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry Co., Ltd. on
Initial Share Repurchase by Way of Centralized bidding transactions (Lin 2022-004) for details.
As of 31 March 2022, the Company initially repurchased 20,942,771 shares by way of
Centralized bidding transactions, representing 1.10% of total share capital (1,911,733,078 shares)
of the Company. The aggregate amount of funds used for the repurchase was RMB 249.97 million
(including the transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry
Co., Ltd. on the Repurchase Progress by way of Centralized bidding transactions (Lin 2022-037)
for details.
3. Matters about Equity Incentives
During the period from 1 January 2022 to 31 March 2022, 4,005,170 shares were granted by
way of independent exercise and registered at the Shanghai Branch of China Securities Depository
and Clearing Corporation Limited with a total of RMB 32,227,676.96 been paid. As of 31 March
2022, the Company's registered capital after change was RMB 1,911,733,078 and its share capital
8 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
was RMB 1,911,733,078, of which, tradable shares subject to selling restrictions were RMB 0,
representing 0% of the Company's registered capital, and tradable shares subject to no selling
restrictions were RMB 1,911,733,078, representing 100% of the Company's registered capital. The
exercise exerted no material impact on the financial conditions and operating results of the Company.
See the Announcement on 2022 Q1 Independent Exercise Results of the 2018 Share Options
Incentive Scheme of Joincare Pharmaceutical Industry Group Co., Ltd. & Changes in Shares (Lin
2022-038) for details.
IV Quarterly Financial Statements
（I）Audit Opinion
□Applicable √N/A
（II）Financial statements
9 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Consolidated Balance Sheet Statement
31 March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item 31 March 2022 31 December 2021
Current assets:
Monetary funds 12,579,072,007.38 11,729,230,390.98
Financial assets held for trading 130,554,453.78 184,638,344.31
Bills receivable 2,221,923,260.75 1,977,286,022.02
Accounts receivable 2,897,888,908.52 2,853,655,551.54
Receivable financing
Prepayments 464,654,180.19 369,232,546.29
Other receivables 80,180,643.34 88,053,825.12
In which: Interests receivable 362,924.63 365,873.64
Dividends receivable
Inventories 2,029,375,758.07 2,078,944,387.68
Contract assets
Held-for-sale assets
Non-current assets due within one year 317,381.23 317,381.23
Other current assets 83,883,266.43 83,986,214.37
Total current assets 20,487,849,859.69 19,365,344,663.54
Non-current assets:
Debt investment
Other debt investment
Long-term receivables 266,904.13 266,904.13
Long-term equity investment 1,447,659,314.56 1,419,349,454.84
Other equity instrument investment 1,186,338,011.05 1,408,882,377.42
Other non-current financial assets
Investment properties 6,191,475.43 6,191,475.43
Fixed assets 4,779,625,073.08 4,839,005,169.81
Construction in progress 903,828,896.94 742,998,743.75
Productive biological assets
Oil & gas assets
Right-of-use assets 51,560,715.90 46,774,759.69
Intangible assets 488,051,308.06 456,782,094.80
Development expenses 846,825,404.25 786,993,435.71
Goodwills 614,468,698.73 614,468,698.73
Long-term prepaid expenses 196,182,282.29 200,715,740.93
Deferred income tax assets 548,328,553.88 552,542,866.71
Other non-current assets 717,916,255.16 663,584,003.80
Total non-current assets 11,787,242,893.46 11,738,555,725.75
Total assets 32,275,092,753.15 31,103,900,389.29
Current liabilities:
Short-term loans 1,655,807,901.10 2,518,484,835.09
Financial liabilities held for trading 211,410.89 143,302.24
Bills payable 1,871,975,736.48 1,582,386,767.93
10 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Accounts payable 846,260,427.00 871,553,210.51
Receipts in advance 23,724,198.29
Contract liabilities 124,089,632.31 234,140,702.29
Payroll payable 323,791,427.31 475,430,823.20
Taxes payable 382,548,978.08 270,618,183.41
Other payables 3,514,175,791.66 3,292,407,989.79
In which: Interests payable
Dividends payable 6,951,984.46 6,951,984.46
Held-for-sale liabilities
Non-current liabilities due within one year 93,590,946.07 91,576,066.33
Other current liabilities 10,663,325.14 15,626,224.29
Total current liabilities 8,846,839,774.33 9,352,368,105.08
Non-current liabilities:
Long-term loans 1,816,661,809.48 826,780,252.78
Bonds payable
Lease liabilities 27,215,133.45 25,071,794.32
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 486,773,175.06 433,543,352.40
Deferred income tax liabilities 179,242,425.75 208,525,905.39
Other non-current liabilities 84,000,000.00 78,000,000.00
Total non-current liabilities 2,593,892,543.74 1,571,921,304.89
Total liabilities 11,440,732,318.07 10,924,289,409.97
Owners’ equity (shareholders’ equity):
Paid-in capital (or equity capital) 1,911,733,078.00 1,907,727,908.00
Other equity instruments
In which: Preferred shares
Perpetual capital securities
Capital reserve 2,303,238,441.65 2,265,357,311.92
Less: Treasury shares 472,590,296.96 222,644,454.50
Other comprehensive income -87,498,451.08 5,387,545.97
Special reserve
Surplus reserve 650,230,145.70 640,821,179.08
Undistributed profits 7,768,862,679.28 7,223,644,166.22
Total owners' equity (shareholders’ equity) 12,073,975,596.59 11,820,293,656.69
attributable to the parent company
Minority shareholders' equity 8,760,384,838.50 8,359,317,322.63
Total owners' equity (shareholders’ equity) 20,834,360,435.08 20,179,610,979.32
Total liabilities and owners' equity (shareholders’ 32,275,092,753.15 31,103,900,389.29
equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
11 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Consolidated income statement
From January to March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item 2022 Jan.-Mar. 2021 Jan.-Mar.
I. Total operating revenues 4,657,343,538.89 4,144,871,763.27
In which: Operating revenues 4,657,343,538.89 4,144,871,763.27
II. Total operating costs 3,650,160,694.91 3,314,653,870.26
In which: Operating costs 1,611,006,712.60 1,448,371,494.49
Operating tax and surcharges 52,198,225.41 50,752,537.45
Selling expenses 1,413,289,256.99 1,342,825,512.04
Administrative expenses 252,854,561.35 223,288,755.24
R&D expenses 351,331,244.23 289,399,163.64
Finance expenses -30,519,305.67 -39,983,592.60
In which: Interest expenses 29,854,923.66 15,859,568.04
Interest income 68,468,649.16 40,497,552.32
Add: Other income 59,138,624.91 77,577,799.31
Investment incomes (enter "-" for loss) 29,176,808.52 21,812,732.70
In which: Income from investment in
15,204,632.53 -1,982,728.44
associates and joint ventures
Income from derecognition of financial
assets at amortized cost
Net exposure hedging gains (enter "-" for
loss)
Income from changes in fair value (enter "-"
-54,151,999.18 -39,393,074.92
for loss)
Credit impairment loss (enter "-" for loss) 217,773.10 -3,611,272.93
Asset impairment loss (enter "-" for loss) -5,309,013.21 -22,802,167.34
Profit on disposal of assets (enter "-" for
-370,357.71 21,927.78
loss)
III. Operating profit (enter "-" for loss) 1,035,884,680.41 863,823,837.62
Add: Non-operating income 2,321,933.96 24,072,371.67
Less: Non-operating expenditures 2,084,578.34 3,257,611.14
IV. Total profit (enter "-" for total loss) 1,036,122,036.03 884,638,598.15
Less: Income tax expenses 173,764,775.30 126,802,840.14
V. Net profit (enter "-" for net loss) 862,357,260.73 757,835,758.01
(1) Classified by continuing operations
1. Net profit from continuing operations (enter "-"
862,357,260.73 757,835,758.01
for net loss)
2. Net profit from discontinuing operations (enter
"-" for net loss)
(2) Classified by attribution to ownership
12 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
1. Net profit attributable to shareholders of the
460,537,813.53 366,890,019.20
parent company (enter "-" for net loss)
2. Profit and loss attributable to minority interests
401,819,447.20 390,945,738.81
(enter "-" for net loss)
VI. Other comprehensive net income after taxation -106,847,774.60 -166,618,134.73
(1) Other comprehensive net income after taxation
-92,885,997.05 -98,483,184.70
attributable to shareholders of the parent company
1. Other comprehensive income not to be
-75,513,312.70 -81,219,999.41
reclassified into profit and loss
1) Changes in re-measurement of defined benefit
plans
2) Other comprehensive income not to be
reclassified into profit and loss under the equity
method
3) Changes in fair value of other equity instrument
-75,513,312.70 -81,219,999.41
investment
4) Changes in fair value of corporate credit risks
2. Other comprehensive income to be reclassified
-17,372,684.35 -17,263,185.29
into profit and loss
1) Other comprehensive income to be reclassified
into profit and loss under the equity method
2) Changes in fair value of other debt investment
3) Amount of financial assets reclassified into
other comprehensive income
4) Provision for credit impairment of other debt
investment
5) Cash flow hedge reserve
6) Foreign currency translation differences -17,372,684.35 -17,263,185.29
7) Others
(2) Other comprehensive net income after taxation
-13,961,777.55 -68,134,950.03
attributable to minority interests
VII. Total comprehensive income 755,509,486.13 591,217,623.29
(1) Total comprehensive income attributable to
367,651,816.48 268,406,834.51
shareholders of the parent company
(2) Total comprehensive income attributable to
387,857,669.65 322,810,788.78
minority interests
VIII. Earnings per share
(1) Basic earnings per share (RMB/share) 0.2411 0.1877
(2) Diluted earnings per share (RMB/share) 0.2410 0.1872
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
13 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
Consolidated Cash Flow Statement
From January to March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project 2022 Jan.-Mar. 2021 Jan.-Mar.
I. Cash flow from operating activities:
Cash received from sales of goods and services rendered 4,614,758,574.74 3,878,119,048.16
Tax refunds 32,240,811.32 28,034,439.16
Other cash received related to operating activities 172,771,264.97 155,840,257.54
Subtotal of cash inflow from operating activities 4,819,770,651.03 4,061,993,744.86
Cash paid for purchase of goods and services rendered 1,165,780,579.10 960,547,682.14
Cash paid to and on behalf of employees 758,821,581.15 623,820,018.21
Taxes paid 420,627,138.84 457,863,727.21
Other cash paid related to operating activities 1,602,636,874.96 1,525,112,803.05
Subtotal of cash outflow in operating activities 3,947,866,174.05 3,567,344,230.61
Net cash flow from operating activities 871,904,476.98 494,649,514.25
II. Cash flows from investing activities:
Cash received from disposal of investments 216,970,980.42 54,739,567.55
Cash received on investment income 6,832,308.83 16,991,426.46
Net cash received from disposal of fixed assets, intangible
346,152.00 330,823.20
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
business units
Other cash received related to investing activities 7,668,394.07 7,743,584.00
Subtotal of cash inflow from investing activities 231,817,835.32 79,805,401.21
Cash paid for purchase and construction of fixed assets,
277,850,093.60 327,336,656.96
intangible assets and other long-term assets
Cash payments for investments 30,338,557.45 20,000,000.00
Net cash paid for acquisition of subsidiaries and other
business units
Other cash paid related to investing activities 1,537,021.94 1,889,662.63
Subtotal of cash outflow in investing activities 309,725,672.99 349,226,319.59
Net cash flow from investment activities -77,907,837.67 -269,420,918.38
III. Cash flow from financing activities:
Cash received from investments 53,414,701.36 350,758,135.59
In which: Cash received by subsidiaries from investment of
minority shareholders
Cash received from borrowings 1,923,486,837.26 660,000,000.00
Other cash received related to financing activities 130,847,366.53 816,504.87
Subtotal of cash inflow from financing activities 2,107,748,905.15 1,011,574,640.46
Cash paid on repayment of debts 1,776,859,803.19 1,002,984,146.53
Cash paid for dividend and profit distribution or interest
19,177,786.10 15,889,262.19
payment
14 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
In which: Dividends and profit paid by subsidiaries to
minority shareholders
Other cash paid related to financing activities 248,996,762.52 535,456,140.59
Subtotal of cash outflow in financing activities 2,045,034,351.81 1,554,329,549.31
Net cash flow from financing activities 62,714,553.34 -542,754,908.85
IV. Effect of changes in foreign exchange rates on cash and
-12,259,201.98 3,666,733.44
cash equivalents
V. Net increase in cash and cash equivalents 844,451,990.66 -313,859,579.54
Add: Opening balance of cash and cash equivalents 11,697,518,141.18 12,122,781,311.49
VI. Closing balance of cash and cash equivalents 12,541,970,131.84 11,808,921,731.95
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
15 / 16
Joincare Pharmaceutical Group Industry Co., Ltd. 2022 First Quarterly Report
(III) Information on adjustment to relevant items in the financial statements at the beginning of
the year of first implementation in respect of the new accounting standards adopted for the first time
starting from 2022
□Applicable√N/A
Notice is hereby given.
Joincare Pharmaceutical Group Industry Co., Ltd.
April 22, 2022
16 / 16
